Drug Profile
BC 19
Alternative Names: BC-19Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Biocortech
- Developer MarcoPolo Pharmaceuticals SA
- Class Alkaloids
- Mechanism of Action Adrenergic receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Major depressive disorder in France
- 31 Mar 2010 Clinical trials in Depression in France (unspecified route)